The price reduction is not in place! Hengrui, Shuanglu and other 60 pharmaceutical enterprises 125 product specifications are suspended from purchasing today!

According to the statistics of official documents issued by the leading group office of centralized procurement of drugs and medical consumables of medical institutions in Liaoning Province, 125 product specifications were suspended from the qualification of network hanging, involving 60 enterprises in total The reason for the suspension of online procurement is that these products fail to meet the requirements of Liaoning Province in the notice on further reducing the tax and price of anticancer drugs on November 29 These products either did not respond to the price reduction requirements, or the reduction did not meet the specified requirements, and some varieties applied for no price reduction but did not provide sufficient supporting materials This also means that, after the way of special procurement of provincial alliance to import anti-cancer drugs, Liaoning Province once again cut the "price reduction" to domestic anti-cancer drugs: those willing to reduce the price and the reduction meets the requirements are qualified to continue trading in Liaoning Province; those unwilling to reduce the price or the reduction is not enough, only one way out What can be predicted is that, according to the current logic, a large-scale price reduction of anti-cancer drugs like this will not be the last time Especially as there may be more than 50 kinds of anticancer drugs next year, including irinotecan hydrochloride, triptoreline acetate and other raw materials will be implemented with zero tariff, and similar price adjustment will be carried out again The price reduction of anticancer drugs is a foregone conclusion 1 After the tax reduction of anticancer drugs, all profits must be released This time, the prices of domestic anticancer drugs in Liaoning Province were lowered in a large range, which originated from a notice issued by the office of the leading group for centralized procurement of drugs and medical consumables of medical institutions in Liaoning Province on its official platform on November 29 The notice requires that all the varieties involved in the list of anticancer drugs (the first batch) in the announcement of the Tariff Commission of the State Council on reducing the import tariff of drugs and the notice of the Ministry of finance, the General Administration of customs, the General Administration of Taxation and the State Drug Administration on the value added tax policy of anticancer drugs, and all the relevant drug manufacturers participating in the centralized purchase of drugs in Liaoning Province, On the basis of tax reduction, we must realize further price reduction The specific principle of price reduction is that for the anti-cancer drugs that have been purchased online in Liaoning Province, the drug manufacturing enterprises shall, within the specified time limit, adjust the price through the methods of commitment declaration, investigation and verification, and social publicity according to the principle of no higher than the lowest price of other provinces in the country that have completed the tax reduction and price reduction Those who do not purchase online in Liaoning Province will open up a green channel, but "tax reduction and price reduction" is the access condition for participating in online purchasing in Liaoning Province This also means that for the manufacturers of anti-cancer drugs, all the benefits brought by the reduction of value-added tax on anti-cancer drugs must be for the benefit of patients The price of drugs should be reduced at least as much as the reduction of tariff and import tax It is no longer feasible to reduce costs and increase profits through the reduction of relevant taxes And Liaoning Province is not a long time for enterprises to declare The announcement is released on November 29, that is, the pharmaceutical companies basically get the notice on the last Friday in November, and from December 3 to 7, that is, the first working week in early December, the companies will make a decision on the price reduction range and report it According to the final results, the price reduction list given by the drug centralized purchase platform of Liaoning Province includes 295 drug product specifications, and finally 172 drugs apply for price reduction actively; four drugs apply for no price reduction, and provide the certification of the accounting firm, which has also been approved by the centralized purchase platform These four drugs are respectively nitorzumab injection of BTB, Paclitaxel injection of Huabei pharmaceutical, xidaban tablet of microchip biological and sitaban for injection in Hangzhou, Central America and East China The rest of the varieties are facing the fate of losing the qualification to hang the net Among them, two drugs applied for no price reduction in the name of "not affected by tax reduction", but they did not provide relevant supporting materials and were not recognized by the centralized purchase platform 57 drugs, belonging to a certain degree of decline, but not meet the requirements of the centralized purchase platform, were also disqualified There are also 66 product specifications, which are completely unresponsive to their price reduction needs This time, some star enterprises, such as Jiangsu Hengrui, lost the qualification of online purchasing According to the notice, Jiangsu Hengrui Pharmaceutical Co., Ltd has suspended trading of 18 product specifications in total, among which 5 product specifications are "unresponsive" and the remaining 13 product specifications are "falling below the requirements" Among them, there are also major varieties of Hengrui, such as two specifications of docetaxel injection, one specification of oxaliplatin for injection and isocyclophosphamide for injection It is worth noting that some enterprises only give up one specification of their products, not the whole variety For example, octreotide acetate injection ranked first in the list of suspended hanging nets There are many manufacturers, including Sinopharm Yixin pharmaceutical The company chose to keep its 1ml: 0.15mg product at a reduced price, while the 1ml: 0.2mg product rule was eliminated because the drop did not meet the requirements In the same way, two specifications of docetaxel injection of Hengrui medicine were eliminated, but another specification was retained in the form of price reduction Part of it is equivalent to giving up the market of its varieties in Liaoning Province Taking octreotide acetate injection as an example, Beijing Sihuan Pharmaceutical Co., Ltd was disqualified from the Internet because it did not respond to the price reduction, while companies with the same product, such as Chengdu shengnuobi, Guoyao Yixin pharmaceutical, Guangdong Xinghao pharmaceutical, etc., all chose to reduce the price It is worth noting that this is not the first time in Liaoning Province this year that the price will be reduced after the centralized mining On August 31, in response to the call for provincial-level special procurement of anticancer drugs launched by the state health insurance bureau and the National Health Commission, Liaoning formed a provincial Procurement Alliance with Shanxi, Jilin, Heilongjiang, Guangxi, Hunan and other 14 provinces (regions) to conduct special procurement of anticancer drugs The difference is that the last special purchase was aimed at imported anti drug drugs Thanks to the bargaining power of "Baotuan" in 14 provinces, 47 imported anticancer drugs including pabolizumab injection were successfully negotiated and included in the procurement scope But at the same time, 10 varieties failed to negotiate Accordingly, these products also lost the qualification of online purchasing in Liaoning Province This time, it is mainly aimed at domestic anti-cancer drugs In fact, from the perspective of the product varieties that are ultimately kept within the scope of centralized drug purchase after price reduction, a situation of original research + n imitations has basically been formed, and the price has also been significantly opened Varieties of different quality levels are within the scope of procurement at the same time, while those of the same quality level are obviously given priority to low prices, and there is basically no market after the varieties of an enterprise are abandoned The situation of similar or alternative products The same with all kinds of procurement in the past, there is no doubt that the national price linkage appeared in the documents of Liaoning Province According to the notice, in the future, in the process of participating in the tax reduction and price reduction of anti-cancer drugs in other provinces, if there is a situation that the price is lower than the online price in Liaoning Province, it is necessary to actively submit a price reduction application to our province within 10 working days If the enterprise fails to report or is reported beyond the prescribed time limit, it will be included in the bad credit record of Liaoning Province's pharmaceutical purchase and sale once verified, and the enterprise will be disqualified from participating in Liaoning Province's pharmaceutical centralized purchase It should be said that in front of the drug companies that want to enter the online purchase, the drug centralized purchase platform still has sufficient voice Next, the price reduction will continue to appear And the next factor that triggers price cuts is likely to be about "taxes." According to Beijing Daily, the Ministry of finance has recently disclosed that China will continue to adjust import and export tariffs on some commodities next year, including the introduction of zero tariffs on various pharmaceutical raw materials It is reported that there are more than 50 kinds of tariffs For example, the tax rates of triptoreline acetate, formetan, exemestane, vinorelbine tartrate, vincristine sulfate, topotecan hydrochloride and irinotecan hydrochloride are all reduced from 4% to 0; the tax rates of lenalidomide, the raw material of anticancer drugs, are reduced from 9% to 0 In addition, the tax rate of penicillamine, riluzole and bosentan, the raw materials of rare disease drugs, was directly reduced from 6.5% to 0; the tax rate of pirfenidone, the raw materials of rare disease drugs, was directly reduced from 9% to 0 Anti serum, other blood and immune products, human vaccines and other pharmaceutical products are also involved this time, and the tax rate is directly reduced from 3% to 0 With reference to the price reduction logic of Liaoning Province, pharmaceutical enterprises enjoy the reduction of tariff and value-added tax, and the next step is to reduce the price in the form of preferential benefits for the people Therefore, it can be expected that with the further adjustment of import and export tariff and value-added tax, the price of anticancer drugs will continue to be lowered, which is basically a foregone conclusion Source: e drug Manager